STAT+: Ophthalmology venture grabs investors’ attention, raises $330 million
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Ollin Biosciences raised $330 million in a Series B round to bankroll late-stage clinical work on its lead eye-disease program, the company told STAT.
- The funding will support a Phase 3 trial of a single therapy aimed at both diabetic macular edema and wet age-related macular degeneration, two conditions the article notes affect millions of Americans and can cause vision loss.
- TCGX and ARCH Venture Partners co-led the round, which Ollin described as one of the largest Series B financings for a biotech in the past two years.
- The investor syndicate blended established biotech investors, a pension fund, and crossover investors — private backers who typically accumulate shares shortly before a company goes public, a signal STAT flags as relevant to Ollin's likely near-term IPO path.
- Ollin is positioned to enter Phase 3 with a single asset targeting two overlapping retinal indications, a dual-indication structure that the source highlights as central to the fundraise's appeal.
Why it matters: At $330 million, the round ranks among the largest biotech Series B financings in two years, and the presence of crossover investors typically precedes an IPO within 12–18 months. A successful Phase 3 would bring a new therapeutic option to millions of Americans at risk of blindness from DME and wet AMD — two indications currently dominated by anti-VEGF injectables.
Ask SkimNews
